FrancophonIA/ELRC3.0 huggingface dataset:
English: This document provides answers to the most frequently asked questions received by the European Medicines Agency (EMA).If the answer to your question is not here, please use our online form: Send a question to EMA.
Estonian: Kui siin ei ole vastust teie küsimusele, kasutage palun meie veebivormi „Saatke küsimus EMA-le“.
English: The Agency then sends this recommendation to the European Commission, which takes a binding decision on whether to grant a marketing authorisation.
Estonian: Seejärel saadab ravimiamet soovituse Euroopa Komisjonile, kes otsustab, kas anda ravimi müügiluba.
English: What does the Agency do?
Estonian: Millega ravimiamet tegeleb?
English: The Agency suggests that you discuss your treatment with a healthcare professional, such as a doctor or pharmacist.
Estonian: Ravimiamet soovitab arutada raviküsimusi tervishoiutöötajaga, näiteks arsti või apteekriga.
English: They are not evaluated by the Agency.
Estonian: Ravimiamet ei tegele nende hindamisega.
English: If you are experiencing a side effect or think you may be experiencing one, you should seek advice from a doctor or pharmacist.
Estonian: Kui teil esineb kõrvaltoime või seda kahtlustate, pöörduge nõu saamiseks arsti või apteekri poole.
English: The Agency does not maintain a list of medical specialists and is unable to advise individual patients on where to seek treatment.
Estonian: Ravimiametil ei ole meditsiinispetsialistide nimekirja ja amet ei nõusta individuaalseid patsiente ravi küsimuses.
English: To find information on nationally authorised medicines, contact the medicines regulatory agency in your country;
Estonian: Riikliku menetlusega müügiloa saanud ravimite teabe leidmiseks võtke ühendust oma riigi ravimiametiga;
English: For information on how to report a side effect in your country, please consult the appropriate authority.
Estonian: Teavet kõrvaltoimete teatise edastamise korra kohta oma riigis küsige vastavalt asutuselt.
English: How are herbal medicines evaluated?
Estonian: Kuidas hinnatakse taimseid ravimeid?
English: You may not be able to obtain a complete list of available treatment options for a specific condition by searching on the Agency's website.
Estonian: Ravimiameti veebilehelt ei pruugi te leida konkreetse terviseseisundi jaoks olemasolevate raviviiside täielikku loetelu.
English: The Agency does not have information on sales figures or prescription numbers for any medicine.
Estonian: Ravimiametil ei ole ühegi ravimi kohta selle müügi või väljakirjutamise andmeid.
English: Can the Agency supply me with branded merchandise?
Estonian: Kas ravimiamet saab varustada mind reklaamkaupadega?
English: Are all medicines approved via the Agency?
Estonian: Kas kõikide ravimite müügiload annab ravimiamet?
English: are prepared by the Committee on Herbal Medicinal Products (HMPC) and contain information about what a herbal medicine is used for, restrictions on its use, its undesirable effects and its interactions with other medicines.
Estonian: taimse ravimi kasutamise eesmärkide, kasutamispiirangute, kõrvaltoimete ja teiste ravimitega koostoimete kohta.
English: Page 8/15
Estonian: Lk 8/15
English: What does the Agency not control?
Estonian: Millega ravimiamet ei tegele?
English: The Agency also recommends that you report any suspected side effects to the national competent authority.
Estonian: Ravimiamet soovitab kõrvaltoimete kahtlusest teavitada riigi ravimiametit.
English: Questions about the availability of medicines
Estonian: Ravimite kättesaadavus
English: • herbal supplements;
Estonian: • taimsete lisanditega;
English: In the European Union (EU), herbal medicines are authorised by medicines regulatory authorities in Member States.
Estonian: Euroopa Liidus annavad taimsete ravimite müügiloa ravimitega tegelevad ametiasutused liikmesriikides.
English: Only medicines evaluated by the Agency are available on the website.
Estonian: Veebilehel on teave ainult nende ravimite kohta, mida ravimiamet on hinnanud.
English: • searching by keyword;
Estonian: • märksõnaotsingu abil;
English: You can also find information on side effects seen with a medicine in the package leaflet.
Estonian: Ravimi kõrvaltoimete teave on ka pakendi infolehel.
English: The Agency also supervises the safety of medicines in the EU after they have been authorised.
Estonian: Pärast ravimitele müügiloa andmist ELis tegeleb ravimiamet ka ravimite ohutusjärelevalvega.
English: It can also give scientific opinions on medicines at the request of Member States or the European Commission.
Estonian: Liikmesriikide või Euroopa Komisjoni palvel võib ravimiamet anda ravimite kohta teaduslikke arvamusi.
English: For information on clinical trials, talk to your doctor or nurse.
Estonian: Küsige selle kohta teavet oma arstilt või meditsiiniõelt.
English: Page 7/15
Estonian: Lk 7/15
English: • medical devices;
Estonian: • meditsiiniseadmetega;
English: • patents on medicines;
Estonian: • ravimitele antavate patentidega;
English: Questions about the Agency
Estonian: Ravimiametit käsitlevad küsimused
English: Page 6/15
Estonian: Lk 6/15
English: Page 4/15
Estonian: Lk 4/15
English: Page 14/15
Estonian: Lk 14/15
English: Page 10/15
Estonian: Lk 10/15
English: Page 12/15
Estonian: Lk 12/15
English: Page 9/15
Estonian: Lk 9/15
English: Page 5/15
Estonian: Lk 5/15
English: Page 13/15
Estonian: Lk 13/15
English: Page 11/15
Estonian: Lk 11/15
English: Page 15/15
Estonian: Lk 15/15
English: The medicines regulatory authorities in Member States may be able to provide information on sales of a medicine.
Estonian: Ravimi müügiteavet võivad teile anda liikmesriikide ravimiametid.
English: • the pricing of medicines;
Estonian: • ravimite hinnakujundusega;
English: These 'Community herbal monographs'
Estonian: Ühenduse ravimtaimede monograafiaid valmistab ette taimsete ravimite komitee (HMPC) ning neis on teave
English: If you wish to use an acronym for the Agency, use 'EMA'.
Estonian: Võite soovi korral kasutada ravimiameti kohta suurtähtlühendit EMA (European Medicines Agency).
English: The full EPAR for Ivabradine Zentiva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Ivabradine Zentiva kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: In patients over 75 years old, a lower starting dose of 2.5 mg twice a day can be used.
Estonian: Üle 75-aastastel patsientidel tohib kasutada väiksemat algannust 2,5 mg kaks korda ööpäevas.
English: Treatment must be stopped if the heart rate decreases persistently below 50 beats per minute or if symptoms of bradycardia (slow heart rate) continue.
Estonian: Ravi tuleb katkestada, kui südame löögisagedus püsib pidevalt alla 50 löögi minutis või kui bradükardia (aeglane pulss) sümptomid jätkuvad.
English: What measures are being taken to ensure the safe and effective use of Ivabradine Zentiva?
Estonian: Mis meetmed võetakse, et tagada Ivabradine Zentiva ohutu ja efektiivne kasutamine?
English: Also, the doctor should consider stopping treatment if the medicine has only a limited effect on reducing symptoms or reducing the heart rate.
Estonian: Arst peab kaalutlema ravi lõpetamist ka siis, kui ravimi toime sümptomite leevendamisele või südame löögisageduse vähendamisele on piiratud.
English: The Committee recommended that Ivabradine Zentiva be approved for use in the EU.
Estonian: Komitee soovitas Ivabradine Zentiva kasutamise Euroopa Liidus heaks kiita.
English: When used for angina, treatment should be stopped if symptoms do not improve after 3 months.
Estonian: Stenokardia korral kasutamisel tuleb ravi peatada, kui 3-kuulise ravi järel sümptomid ei leevene.
English: Ivabradine Zentiva ivabradine
Estonian: Ivabradine Zentiva ivabradiin
English: Ivabradine Zentiva is also used in patients with long-term heart failure (when the heart cannot pump enough blood to the rest of the body) and a normal heart rhythm whose heart rate is at least 75 beats per minute.
Estonian: Ravimit Ivabradine Zentiva kasutatakse ka pikaajalise südamepuudulikkusega (süda ei suuda pumbata organismi piisaval hulgal verd) patsientidel, kellel on normaalne südamerütm ja kelle südame löögisagedus on vähemalt 75 lööki minutis.
English: Ivabradine Zentiva is available as tablets (5 and 7.5 mg) and can only be obtained with a prescription.
Estonian: Ravimit Ivabradine Zentiva turustatakse tablettidena (5 mg ja 7,5 mg).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ivabradine Zentiva have been included in the summary of product characteristics and the package leaflet.
Estonian: Ivabradine Zentiva ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Ivabradine Zentiva is a heart medicine used to treat the symptoms of long-term stable angina (pains to the chest, jaw and back, brought on by physical effort) in adults with coronary artery disease (heart disease caused by blockage of the blood vessels that supply the heart muscle).
Estonian: Ravimit Ivabradine Zentiva kasutatakse pikaajalise stabiilse stenokardia (füüsilise pingutuse tulemusel tekkiv rindkere-, lõua- või seljavalu) sümptomaatiliseks raviks südame isheemiatõvega (südamelihast verega varustavate veresoonte ummistus) täiskasvanutel.
English: What is Ivabradine Zentiva and what is it used for?
Estonian: Mis on Ivabradine Zentiva ja milleks seda kasutatakse?
English: This is a summary of the European public assessment report (EPAR) for Ivabradine Zentiva.
Estonian: See on ravimi Ivabradine Zentiva Euroopa avaliku hindamisaruande kokkuvõte.
English: By lowering the heart rate, Ivabradine Zentiva reduces the stress on the heart, thereby slowing the progression of heart failure and improving symptoms.
Estonian: Südame löögisagedust aeglustades vähendab Ivabradine Anpharm südame koormust, pidurdades südamepuudulikkuse süvenemist ja leevendades sümptomeid.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Ivabradine Zentiva has been shown to have comparable quality and to be bioequivalent to Procoralan.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Ivabradine Zentiva võrreldav kvaliteet ja bioekvivalentsus ravimiga Procoralan.
English: Because Ivabradine Zentiva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Ivabradine Zentiva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: It is used in combination with standard therapy including beta-blockers, or in patients who cannot be treated with beta-blockers.
Estonian: Seda kasutatakse koos beetablokaatoreid sisaldava tavapärase raviga või patsientidel, keda ei saa ravida beetablokaatoritega.
English: Other information about Ivabradine Zentiva
Estonian: Muu teave Ivabradine Zentiva kohta
English: This means that Ivabradine Zentiva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Procoralan.
Estonian: See tähendab, et Ivabradine Zentiva on sarnane võrdlusravimiga Procoralan, millel juba on Euroopa Liidus müügiluba.
English: For more information about treatment with Ivabradine Zentiva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Ivabradine Zentiva toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For practical information about using Ivabradine Zentiva, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate ravimi Ivabradine Zentiva kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: It is not intended to provide practical advice on how to use Ivabradine Zentiva.
Estonian: Hindamisaruandes ei anta ravimi Ivabradine Zentiva kasutamise praktilisi nõuandeid.
English: Ivabradine Zentiva contains the active substance ivabradine.
Estonian: Ivabradine Zentiva sisaldab toimeainena ivabradiini.
English: Because Ivabradine Zentiva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Procoralan.
Estonian: Et Ivabradine Zentiva on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Ivabradine Zentiva bioekvivalentsust võrdlusravimiga Procoralan.
English: Why is Ivabradine Zentiva approved?
Estonian: Miks Ivabradine Zentiva heaks kiideti?
English: It is used either in patients who cannot take beta-blockers (another type of medicine to treat angina) or in combination with a beta-blocker in patients whose disease is not controlled by a beta-blocker alone.
Estonian: Ravimit kasutatakse patsientidel, kes ei saa võtta beetablokaatoreid (samuti stenokardiaravim), või kombinatsioonis beetablokaatoritega patsientidel, kellel ainult beetablokaatorite kasutamine ei ole tulemusi andnud.
English: Ivabradine Zentiva therefore reduces or prevents the symptoms of angina.
Estonian: Sellega vähendab Ivabradine Zentiva stenokardiasümptomeid või ennetab neid.
English: The active substance in Ivabradine Zentiva, ivabradine, blocks the ‘If current' in the sinus node, the natural ‘pacemaker' that regulates the heart rate.
Estonian: Ivabradine Zentiva toimeaine ivabradiin blokeerib If-voolu südamerütmi reguleerivas siinussõlmes.
English: How is Ivabradine Zentiva used?
Estonian: Kuidas ravimit Ivabradine Zentiva kasutatakse?
English: How has Ivabradine Zentiva been studied?
Estonian: Kuidas ravimit Ivabradine Zentiva uuriti?
English: What are the benefits and risks of Ivabradine Zentiva?
Estonian: Milles seisneb Ivabradine Zentiva kasulikkus ja mis riskid ravimiga kaasnevad?
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Estonian: Üksikasjalikku teavet selle veterinaarravimi kohta leiab Euroopa Ravimiameti kodulehelt http://www.ema.europa.eu/.
English: MANUFACTURER'S BATCH NUMBER Lot.
Estonian: TOOTJAPOOLNE PARTII NUMBER Lot:
English: 3421 TV Oudewater The Netherlands
Estonian: 3421 TV Oudewater Holland
English: ATCvet code: QN05CM18.
Estonian: ATC-vet kood: QN05CM18.
English: Address: Forellenweg 16 4941 SJ Raamsdonksveer The Netherlands
Estonian: Aadress: Forellenweg 16 4941 SJ Raamsdonksveer Holland
English: MARKETING AUTHORISATION NUMBER(S) EU/2/16/198/002
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/2/16/198/002
English: MARKETING AUTHORISATION NUMBER(S) EU/2/16/198/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/2/16/198/001
English: 10 DATE OF REVISION OF THE TEXT <{MM/YYYY}>
Estonian: TEKSTI ÜLEVAATAMISE KUUPÄEV <{PP/AAAA}>
English: It is recommended that animals are fasted for 12 hours prior to Sedadex administration.
Estonian: Soovitatav on hoida loomi söömata 12 tundi enne Sedadexi manustamist.
English: Manufacturer responsible for batch release: Name:
Estonian: Partii vabastamise eest vastutav tootja: Nimi:
English: Shelf-life after first opening the container: 56 days.
Estonian: Kõlblikkusaeg pärast viaali esmast avamist: 56 päeva.
English: 4.10 Overdose (symptoms, emergency procedures, antidotes)
Estonian: Üleannustamine (sümptomid, esmaabi, antidoodid)
English: Pharmacotherapeutic group: Psycholeptics, hypnotics and sedatives.
Estonian: Farmakoterapeutiline grupp: psühholeptikumid, hüpnootikumid ja sedatiivid.
English: Marketing authorisation holder: Name:
Estonian: Müügiloa hoidja: Nimi:
English: Sedadex contains dexmedetomidine as the active substance, which produces sedation and analgesia in dogs and cats.
Estonian: Sedadex sisaldab toimeainena deksmedetomidiini, mis kutsub esile sedatsiooni ja analgeesiat koertel ja kassidel.
English: UANTITY ml
Estonian: OIMEAINE ml
English: PHARMACEUTICAL FORM Solution for injection Clear, colourless solution.
Estonian: RAVIMVORM Süstelahus Selge, värvitu lahus.
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) 1 ml contains:
Estonian: TOIMEAINETE JA ABIAINETE SISALDUS 1 ml sisaldab:
English: Sodium hydroxide (E 524) (for pH adjustment)
Estonian: Naatriumhüdroksiid (E 524) (pH regulaator)
English: Hydrochloric acid (E507) (for pH adjustment)
Estonian: Vesinikkloriidhape (E 507) (pH regulaator)
English: Colourless Type I glass vials of 10 ml closed with a coated bromobutyl rubber stopper and aluminium cap in a carton box.
Estonian: Värvitust I tüüpi klaasist 10 ml viaalid, mis on suletud kaetud bromobutüülkummist korgiga ja alumiiniumkattega, pappkarbis.
English: The specific α2adrenoceptor antagonist, atipamezole, which is approved for use in animals, has been used in humans only experimentally to antagonize dexmedetomidine-induced effects.
Estonian: Väikeloomadel kasutamiseks heakskiidetud spetsiifilist α2-retseptori agonisti atipamesooli on inimesel deksmedetomidiini toime kõrvaldamiseks kasutatud ainult eksperimentaalselt.
English: Cat Weight
Estonian: ISU KAALU
English: 1 ml con Dexmed (equivale
Estonian: 1 ml sisa Deksmed (vastab 0
English: (mcg/kg)
Estonian: (µg /kg)
English: 0.1 m 0.08 m
Estonian: 0,1 m ehte.
English: Dogs: IV Cats: IM
Estonian: Koer: i.m Kass: i.m
English: e
Estonian: VE
English: HT, BY VOL
Estonian: U, MAHU V
English: HE VETER injection ydrochloride
Estonian: ARRAVIMI süst ydrochloridum
English: PRODULAB PHARMA B.V. Forellenweg 16, Raamsdonksveer 4941SJ
Estonian: Raamsdonksveer 4941SJ
English: N(S)
Estonian: S(ED)
English: AME OF TH x 0.1 mg/ml s etomidine hy
Estonian: x 0,1 mg/ml s etomidini hy
English: TA Dogs an
Estonian: Koerad Kaal
English: Q 0.5 mg/m
Estonian: TO 0,5 mg/m
English: AME OF TH x 0.5 mg/ml s etomidine hy
Estonian: x 0,5 mg/ml s etomidini hy
English: PRODUCT ts
Estonian: s kasutamise
English: CKAGING U
Estonian: AKENDI SI
English: IVE AND O
Estonian: E(TE) JA AB
English: For higher weight ranges, use Sedadex 0.5 mg/ml and its dosing tables.
Estonian: Suuremate kehamasside korral kasutage Sedadex 0,5 mg/ml ja selle annustamistabeleid
English: 4.2 Indications for use, specifying the target species Non-invasive, mildly to moderately painful, procedures and examinations which require restraint, sedation and analgesia in dogs and cats.
Estonian: Näidustused, määrates kindlaks vastavad loomaliigid Sedatsiooni ja analgeesiat vajavad mitteinvasiivsed, kergelt või mõõdukalt valulikud ja liikumatut asendit nõudvad protseduurid ja uuringud koertel ja kassidel.
English: Advice to physicians: Sedadex is an α2-adrenoreceptor agonist, symptoms after absorption may involve clinical effects including dose-dependent sedation, respiratory depression, bradycardia, hypotension, a dry mouth, and hyperglycaemia.
Estonian: Pärast imendumist võivad tekkida järgmised sümptomid: doosist sõltuv sedatsioon, hingamise depressioon, bradükardia, hüpotensioon, suukuivus ja hüperglükeemia.
English: Major biotransformations in the dog include hydroxylation, glucuronic acid conjugation and N-methylation in the liver.
Estonian: Koeral toimub ravimi biotransformatsioon peamiselt maksas ning hõlmab hüdroksüleerimist, glükuroonhappega konjugeerimist ja N-metüleerimist.
English: Q 0.1 mg/m
Estonian: TO 0,1 mg/m
English: Excipient(s): Methyl parahydroxybenzoate (E 218)
Estonian: (vastab 0,08 mg deksmedetomidiinile) Abiained: metüülparahüdroksübensoaat (E 218)
English: 0.5 m 0.42 m
Estonian: 0,5 m ehte.
English: OF ADMINI
Estonian: VÕI ANNUS
English: The dose volume of atipamezole at the concentration of 5 mg/ml is one fifth (1/5) of the dose volume of Sedadex 0.1 mg/ml that was given to the dog, regardless of route of administration of Sedadex.
Estonian: Atipamesooli annuse maht kontsentratsioonil 5 mg/ml on üks viiendik (1/5) koerale manustatud Sedadexi 0,1 mg/ml mahust sõltumata Sedadexi manustamisteest.
English: The dose volume of atipamezole at the concentration of 5 mg/ml equals the dose volume of Sedadex 0.5 mg/ml that was given to the dog, regardless of route of administration of Sedadex.
Estonian: Atipamesooli annuse maht kontsentratsioonil 5 mg/ml on võrdne koerale manustatud Sedadexi 0,5 mg/ml mahuga sõltumata Sedadexi manustamisteest.
English: TE
Estonian: US
English: METHOD AN ntravenous or tramuscular u e package lea
Estonian: MISVIIS JA või intramus rne mist lugege p
English: ECIES
Estonian: JÄRGI
English: OUTE(S) O V , IM M
Estonian: I NIMETUS oertele ja kas m
English: NA
Estonian: TO
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Sedadex 0.5 mg/ml solution for injection for dogs and cats
Estonian: VETERINAARRAVIMI NIMETUS Sedadex 0,5 mg/ml süstelahus koertele ja kassidele
English: NDICATION
Estonian: SISALDUS
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Sedadex 0.1 mg/ml solution for injection for dogs and cats
Estonian: VETERINAARRAVIMI NIMETUS Sedadex 0,1 mg/ml süstelahus koertele ja kassidele
English: CKAGE
Estonian: ARRAVIMI
English: EATMENT
Estonian: ETERINAA
English: The dose volume of atipamezole at the concentration of 5 mg/ml is one-tenth (1/10) the volume of Sedadex 0.1 mg/ml that was given to the cat.
Estonian: Atipamesooli annuse maht kontsentratsioonil 5 mg/ml on üks kümnendik (1/10) kassile manustatud Sedadexi 0,1 mg/ml mahust.
English: EDICINAL
Estonian: laasviaal
English: Propyl parahydroxybenzoate
Estonian: süstelahus ko ydrochloridum
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Sedadex 0.5 mg/ml solution for injection for dogs and cats dexmedetomidine hydrochloride
Estonian: VETERINAARRAVIMI NIMETUS Sedadex 0,5 mg/ml süstelahus koertele ja kassidele deksmedetomidiinvesinikkloriid
English: ARGET SP d cats
Estonian: DED ANDM ETUL SISEP
English: ATION
Estonian: NÄIDUSTUSED
English: Dogs: in Cats: int Read the
Estonian: Koer: int Kass: int Enne rav
English: The dose volume of atipamezole at the concentration of 5 mg/ml is one-half the volume of Sedadex 0.5 mg/ml that was given to the cat.
Estonian: Atipamesooli annuse maht kontsentratsioonil 5 mg/ml on pool kassile manustatud Sedadexi 0,5 mg/ml mahust.
English: EXP {m Once bro
Estonian: EXP: {k Pärast ko
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Sedadex 0.1 mg/ml solution for injection for dogs and cats dexmedetomidine hydrochloride
Estonian: VETERINAARRAVIMI NIMETUS Sedadex 0,1 mg/ml süstelahus koertele ja kassidele deksmedetomidiinvesinikkloriid
English: WAL PERIO
Estonian: AKENDI SU
English: 4.11 Withdrawal period(s)
Estonian: TEKSTI ÜLEVAATAMISE KUUPÄEV <{KK/AAAA}>
English: ND ROUTE r intramuscu use aflet before u
Estonian: -TEE(D) skulaarne akendi infole
English: ONLY”
Estonian: KS”
English: The dose for cats is 40 micrograms dexmedetomidine hydrochloride/kg bw equal to a dose volume of 0.08 ml Sedadex/kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.
Estonian: Deksmedetomidiinvesinikkloriidi annus kassidel on 40 mikrogrammi kg kehamassi kohta, mis vastab 0,08 ml Sedadexile kg kehamassi kohta.
English: PACKAGE LEAFLET FOR Sedadex 0.5 mg/ml solution for injection for dogs and cats
Estonian: PAKENDI INFOLEHT Sedadex 0,5 mg/ml süstelahus koertele ja kassidele
English: The dose volume of atipamezole at the concentration of 5 mg/ml is one-half (1/2) the volume of Sedadex 0.5 mg/ml that was given to the cat.
Estonian: Atipamesooli annuse maht kontsentratsioonil 5 mg/ml on pool (1/2) kassile manustatud Sedadexi 0,5 mg/ml mahust.
English: C.
Estonian: m.
English: N
Estonian: S
English: C
Estonian: K
English: BSTANCES
Estonian: TERINAAR
English: The dose for cats is 40 micrograms dexmedetomidine hydrochloride/kg bw equal to a dose volume of 0.4 ml Sedadex/kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.
Estonian: Deksmedetomidiinvesinikkloriidi annus kassidel on 40 mikrogrammi kg kehamassi kohta, mis vastab 0,4 ml Sedadexile kg kehamassi kohta.
English: STRATION
Estonian: UTAMISEK
English: TATEMEN ntains: detomidine hy ent to dexme
Estonian: MÄRGE „AI vet. eterinaarseks
English: PARTIC Cardboa
Estonian: PAKENDI INFOLEHT
English: IF NECESS use.
Estonian: mist kasutada